지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 54 - 61 (8page)
이용수
초록· 키워드
오류제보하기
Introduction: Bisphosphonates is used widely for the treatment of the Paget’s disease, multiple myeloma, bone metastases of malignant tumors with the prevention of pain and their pathological fracture. However, it was recently suggested that bisphosphonates related osteonecrosis of the jaw (BRONJ) is a side effect of bisphosphonate use.
Materials and Methods: Twenty-four individuals, who were referred to the Department of Oral and Maxillofacial surgery, Dankook University Dental Hospital, were selected from those who had exposed bone associated with bisphosphonates from January, 2005 to December, 2009 according to the criteria of American Association of Oral and Maxillofacial Surgeons (AAOMS) for BRONJ. The patients group consisted of 7 males and 17females between the age of 46 to 78 years (average 61.8 years). Each patient had panoramic imaging, computed tomography (CT), whole body bone scanning performed for a diagnosis and biopsy sampling from the necrotizing tissue. C-terminal cross-linking telopeptide of type I collagen (CTX)level of patients who had undergone surgical intervention was measured 7 days before surgery.
Results: The main cause of bone exposure was post-extraction (15), chronic periodontitis (4), persistent irritation of the denture (3). Twenty people had undergone BRONJ treatment for two to eight months except for 4 people who had to maintain the bisphosphonates treatment to prevent a metastasis and bone trabecular pain with medical treatment. When the bisphosphonate treatment was suspended at least for 3 months and followed up according to the AAOMS protocols, the exposed necrotizing bones were found to be covered by soft tissue.
Conclusion: Prevention therapy, interruption of bisphophonates for at least 3 months and cooperation with the physician for conservative treatment are the essential for treating BRONJ patient with high risk factors. The CTX level of BRONJ patients should be checked before undergoing surgical intervention. Surgical treatments should be delayed in the case of a CTX level <150 pg/mL.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws / 2007 / American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-re
Alakangas A / 2002 / Alendronate disturbs vesicular trafficking in osteoclasts / Calcif Tissue Int 70 : 40 ~ 47
Badros A / 2006 / Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors / J Clin Oncol 24 : 945 ~ 952
Bedogni A / 2008 / Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology / Oral Surg Oral Med Oral Pathol Oral Radiol
Black DM / 2007 / HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis / N Engl J Med 356 : 1809 ~ 1822
Alakangas A / 2002 / Alendronate disturbs vesicular trafficking in osteoclasts / Calcif Tissue Int 70 : 40 ~ 47
Badros A / 2006 / Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors / J Clin Oncol 24 : 945 ~ 952
Bedogni A / 2008 / Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology / Oral Surg Oral Med Oral Pathol Oral Radiol
Black DM / 2007 / HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis / N Engl J Med 356 : 1809 ~ 1822
이 논문의 저자 정보
최근 본 자료
댓글(0)
0